p300 mediates cellular resistance to doxorubicin in bladder cancer

Molecular Medicine Reports

Volumn 5, Issue 1, 2012, Pages 173-176

  Takeuchi, Ario ^a   Shiota, Masaki ^a   Tatsugami, Katsunori ^a   Yokomizo, Akira ^a   Tanaka, Shingo ^a   Kuroiwa, Kentaro ^a   Eto, Masatoshi ^b   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Cisplatin; Doxorubicin; p300

Indexed keywords

DOXORUBICIN; PROTEIN P300; SMALL INTERFERING RNA;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER CELL RESISTANCE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EXPOSURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PROTEIN EXPRESSION; TUMOR RECURRENCE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; E1A-ASSOCIATED P300 PROTEIN; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS;

EID: 84855233604     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.593     Document Type: Article

References (21)

1. Jacobs BL, Lee CT and Montie JE: Bladder cancer in 2010: How far have we come? CA Cancer J Clin 60: 244-272, 2010.
2. Vaishampayan U: Systemic therapy of advanced urothelial cancer. Curr Treat Options Oncol 10: 256-266, 2009.
3. Naito S, Yokomizo A and Koga H: Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol 6: 427-439, 1999. (Pubitemid 29425476)
4. Kimiya K, Naito S, Soejima T, et al.: Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J Urol 148: 441-445, 1992.
5. Hasegawa S, Abe T, Naito S, et al.: Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71: 907-913, 1995.
6. Eckner R, Ewen ME, Newsome D, et al.: Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 8: 869-884, 1994.
7. Giles RH, Peters DJ and Breuning MH: Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14: 178-183, 1998. (Pubitemid 28244241)
8. Giordano A and Avantaggiati ML: p300 and CBP: partners for life and death. J Cell Physiol 181: 218-230, 1999. (Pubitemid 29463637)
9. Goodman RH and Smolik S: CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553-1577, 2000. (Pubitemid 30460905)
10. Chan HM and La Thangue NB: p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114: 2363-2373, 2001. (Pubitemid 32684792)
11. Ogryzko VV, Schiltz RL, Russanova V, et al.: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959, 1996. (Pubitemid 26404293)
12. Ghosh AK and Varga J: The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 213: 663-671, 2007. (Pubitemid 350058260)
13. Yang XJ, Ogryzko VV, Nishikawa J, et al.: A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382: 319-324, 1996. (Pubitemid 26260451)
14. Shiota M, Yokomizo A, Tada Y, et al.: P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance. Cancer Sci 101: 1797-1806, 2010.
15. Shiota M, Yokomizo A, Kashiwagi E, et al.: Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Sci 101: 1177-1185, 2010.
16. Shiota M, Song Y, Yokomizo A, et al.: Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation. Clin Cancer Res 16: 5654-5663, 2010.
17. Kalyanaraman B, Joseph J, Kalivendi S, et al.: Doxorubicin-induced apoptosis: Implications in cardiotoxicity. Mol Cell Biochem 234-235: 119-124, 2002. (Pubitemid 34777848)
18. Aluise CD, Sultana R, Tangpong J, et al.: Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: Role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 678: 147-156, 2010.
19. Rybak LP, Whitworth CA, Mukherjea D, et al.: Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 226: 157-167, 2007. (Pubitemid 46428033)
20. Chirino YI and Pedraza-Chaverri J: Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61: 223-242, 2009.
21. Iyer NG, Ozdag H and Caldas C: p300/CBP and cancer. Oncogene 23: 4225-4231, 2004. (Pubitemid 38758588)